Xeris Biopharma exchanges $23 million in convertible notes for cash and stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall St futures muted as US-Iran impasse lifts oil prices
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- On Holding shares fall sharply after Q2 sales miss
- Citi bullish on MongoDB stock, expects 'significant positive estimate revisions'
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Xeris Biopharma Announces Private Exchange of Convertible Notes
June 11, 2026 7:00 AM EDT
Eliminates approximately $23 million of debt, resulting in approximately $2 million in annual interest savings
Principal to be paid in cash, remainder in common stock
CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028 (the Notes). Pursuant to the exchange agreements, Xeris has agreed, subject to customary closing conditions, to... More
